Myasthenia gravis is a rare disease where the immune system attacks the communication between nerves and muscles, causing weakness. It often affects the muscles used for eye movement, facial ...
Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, focus on the best and most effective methods of engaging patients who have ...
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART’s sustained ...
The Food and Drug Administration (FDA) has sent out 12 more Untitled Letters to pharma companies amid its ongoing crackdown ...
Temple University is granted summary judgment on the ADA retaliation claim of an assistant professor suffering from myasthenia gravis who was denied tenure, because the discrimination complaint he ...
Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with ...
An update from Argenx Se ( (ARGX) ) is now available. On October 15, 2025, Argenx SE announced its participation in the 2025 AANEM Annual Meeting and MGFA Scientific Session, where it will present ...
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third-quarter 2025 investor letter. A ...
From the star who graced the hallowed halls of General Hospital f or half a century, to the “Queen of Soaps” who was snubbed ...
Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.
While the M&A emphasis is currently on life sciences, a business unit which sells products used in R&D and manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback